Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.

Driessen EMC, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R.

Leukemia. 2017 Dec;31(12):2854. doi: 10.1038/leu.2017.279.

PMID:
29210366
2.

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.

Kerstjens M, Driessen EM, Willekes M, Pinhanços SS, Schneider P, Pieters R, Stam RW.

Oncotarget. 2017 Feb 28;8(9):14835-14846. doi: 10.18632/oncotarget.11730.

3.

Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia.

Driessen EM, Pinhanços SS, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW.

Eur J Cancer. 2016 Apr;57:87-90. doi: 10.1016/j.ejca.2015.12.031. Epub 2016 Feb 19. No abstract available.

PMID:
26901613
4.

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.

Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R.

Leukemia. 2016 May;30(5):1184-7. doi: 10.1038/leu.2015.246. Epub 2015 Sep 15. No abstract available. Erratum in: Leukemia. 2017 Dec;31(12 ):2854.

PMID:
26369984
5.

Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia.

van der Linden MH, Seslija L, Schneider P, Driessen EM, Castro PG, Stumpel DJ, van Roon E, de Boer J, Williams O, Pieters R, Stam RW.

PLoS One. 2015 Mar 20;10(3):e0120326. doi: 10.1371/journal.pone.0120326. eCollection 2015.

6.

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW.

Haematologica. 2013 Jun;98(6):937-44. doi: 10.3324/haematol.2012.067983. Epub 2013 Feb 12.

7.

CBL mutations do not frequently occur in paediatric acute myeloid leukaemia.

Coenen EA, Driessen EM, Zwaan CM, Stary J, Baruchel A, de Haas V, de Bont ES, Reinhardt D, Kaspers GJ, Arentsen-Peters ST, Meyer C, Marschalek R, Pieters R, Stam RW, van den Heuvel-Eibrink MM.

Br J Haematol. 2012 Dec;159(5):577-84. doi: 10.1111/bjh.12068. Epub 2012 Oct 1.

PMID:
23025505
8.

Long-term survival after significant treatment reduction in a patient with CBF-AML.

Driessen EM, van der Velden VH, Catsman-Berrevoets CE, van den Heuvel-Eibrink MM, Beishuizen A.

Pediatr Blood Cancer. 2011 Feb;56(2):325-6. doi: 10.1002/pbc.22854. Epub 2010 Nov 11. No abstract available.

PMID:
21157900

Supplemental Content

Loading ...
Support Center